Nucleus Investment Insights with Patrick Poke of Livewire markets
As part of Nucleus' webinar and podcast series "Nucleus Investment Insights", we often seek to have various industry members as guests to gain further insights.
On this week's episode, we're pleased to have Livewire editor Patrick Poke joining us.
Falling broker and industry research, what to make of writer biases and motives, growing interest in International equities among investors, and the media silence of Superannuation fund managers is just some of what's on the agenda in this episode.
Or simply search "Nucleus Investment Insights" on your preferred podcast platform
Topic timestamps are included in the YouTube and Podcast descriptions
We hope you enjoy, feel free to subscribe for future episodes if you did
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
Damien runs asset allocation and global stock portfolios for Nucleus Super, Nucleus Ethical and Nucleus Wealth. His 25 year+ career includes Global Quant at Schroders, Strategy at Wilson HTM & co-founder of Aegis.
........
The information on this blog contains general information and does not take into account your personal objectives, financial situation or needs. Past performance is not an indication of future performance. Damien Klassen is an authorised representative of Nucleus Wealth Management, a Corporate Authorised Representative of Nucleus Advice Pty Ltd - AFSL 515796.
3 topics
1 contributor mentioned
Damien runs asset allocation and global stock portfolios for Nucleus Super, Nucleus Ethical and Nucleus Wealth. His 25 year+ career includes Global Quant at Schroders, Strategy at Wilson HTM & co-founder of Aegis.
Expertise
Damien runs asset allocation and global stock portfolios for Nucleus Super, Nucleus Ethical and Nucleus Wealth. His 25 year+ career includes Global Quant at Schroders, Strategy at Wilson HTM & co-founder of Aegis.
Expertise
Comments
Comments
Sign In or Join Free to comment
most popular
Equities
The 7 zombie companies lurking on the ASX 300
Livewire Markets